Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.:: NCCLS collaborative evaluation

被引:73
作者
Espinel-Ingroff, A
Bartlett, M
Chaturvedi, V
Ghannoum, M
Hazen, KC
Pfaller, MA
Rinaldi, M
Walsh, TJ
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Med Mycol Res Lab, Richmond, VA 23298 USA
[2] Univ Virginia, Hlth Syst, Charlottesville, VA USA
[3] Indiana Univ, Sch Med, Indianapolis, IN USA
[4] Case Western Reserve Univ, Univ Hosp Cleveland, Cleveland, OH 44106 USA
[5] New York Hlth Dept, Albany, NY USA
[6] Univ Iowa, Coll Med, Iowa City, IA USA
[7] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA
[8] NCI, Bethesda, MD 20892 USA
关键词
D O I
10.1128/AAC.45.6.1828-1835.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The most important role of susceptibility testing is to identify potentially resistant isolates for the agent being evaluated, Standard testing guidelines recently have been proposed for antifungal susceptibility testing of filamentous fungi (molds), This collaborative (eight centers) study evaluated further newly proposed guidelines (NCCLS, proposed standard M38-P, 1998) and other testing conditions for antifungal susceptibility testing of Aspergillus spp. to itraconazole and three new triazoles, posaconazole CSCH56592), ravuconazole (BMS-207147), and voriconazole. MICs of itraconazole, posaconazole, ravuconazole, and voriconazole for 15 selected isolates of three species of Aspergillus (A. fumigatus, A. flavus, and A. terreus) with well documented in vitro, clinical, or animal data were determined in each center by using four medium formulations (standard RPMI-1640 [RPMI], RPMI with 2% dextrose, antibiotic medium 3 [M3], and M3 with 2% dextrose) and two criteria of MIC determination (complete [MIC-0s] and prominent [MIC-2s] growth inhibition) at 24, 48, and 72 h, The highest reproducibility (92 to 99%) was seen dth the standard RPM[I and M3 media. Moreover, the distinction between itraconazole-resistant MICs of >8 mug/ml for clinically resistant strains) and -susceptible (MICs of 0.03 to 1 mug/ml) isolates, as well as between a voriconazole-resistant laboratory mutant and other isolates (voriconazole MICs of 2 to >8 versus 0.12 to 2 mug/ml), was more consistently evident with the standard RPMI medium and when MIG-Os were determined at 48 h, These results provide further refinement of the testing guidelines for susceptibility testing of Aspergillus spp. and warrant consideration for inclusion in the future NCCLS document M38-A.
引用
收藏
页码:1828 / 1835
页数:8
相关论文
共 31 条
[1]   Quality control limits for broth microdilution susceptibility tests of ten antifungal agents [J].
Barry, AL ;
Pfaller, MA ;
Brown, SD ;
Espinel-Ingroff, A ;
Ghannoum, MA ;
Knapp, C ;
Rennie, RP ;
Rex, JH ;
Rinaldi, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3457-3459
[2]  
Chumpitazi BFF, 2000, J CLIN MICROBIOL, V38, P438
[3]   Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia [J].
Clancy, CJ ;
Nguyen, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1289-1290
[4]   Itraconazole resistance in Aspergillus fumigatus [J].
Denning, DW ;
Venkateswarlu, K ;
Oakley, KL ;
Anderson, MJ ;
Manning, NJ ;
Stevens, DA ;
Warnock, DW ;
Kelly, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1364-1368
[5]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414
[6]   Introduction to antifungal drugs [J].
Dismukes, WE .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :653-657
[7]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[8]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956
[9]   COMPARATIVE AND COLLABORATIVE EVALUATION OF STANDARDIZATION OF ANTIFUNGAL SUSCEPTIBILITY TESTING FOR FILAMENTOUS FUNGI [J].
ESPINELINGROFF, A ;
DAWSON, K ;
PFALLER, M ;
ANAISSIE, E ;
BRESLIN, B ;
DIXON, D ;
FOTHERGILL, A ;
PAETZNICK, V ;
PETER, J ;
RINALDI, M ;
WALSH, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :314-319
[10]   Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi [J].
EspinelIngroff, A ;
Bartlett, M ;
Bowden, R ;
Chin, NX ;
Cooper, C ;
Fothergill, A ;
McGinnis, MR ;
Menezes, P ;
Messer, SA ;
Nelson, PW ;
Odds, FC ;
Pasarell, L ;
Peter, J ;
Pfaller, MA ;
Rex, JH ;
Rinaldi, MG ;
Shankland, GS ;
Walsh, TJ ;
Weitzman, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :139-143